Introduction
BRD4 is a member of the bromodomain and extraterminal (BET) family of chromatin reader proteins. BET proteins feature characteristic tandem N-terminal bromodomains that function to interact with N-acetyl lysine residues on histones and nuclear proteins (1) (2) (3) (4) . Bromodomainmediated interactions localize BRD4 to discrete chromosomal locations, facilitating the recruitment of transcriptional regulatory complexes, such as the general initiation cofactor Mediator and the Positive Transcription Elongation Factor b (P-TEFb) (5) (6) (7) . Studies involving chromatin immunoprecipitation coupled with DNA-sequencing (ChIP-seq) have revealed a highly asymmetric genome-wide binding pattern of BRD4, with most chromatin-bound BRD4 localizing to enhancer elements. In particular, BRD4 has been shown to predominately bind enhancer elements, which are important for cell-type specification and oncogenesis (8, 9) .
The discovery of lysine-mimetic small molecules capable of disrupting the chromatin binding activity of BET bromodomains was a crucial step towards uncovering the cancer supporting activity of BRD4 (10) (11) (12) . In hematologic malignancies such as AML, MM and DLBCL, the misregulated expression of hematopoietic transcription factors is particularly important. BRD4 maintains and facilitates oncogenic transcription by interacting directly with transcription factors, and/or co-occupying transcription factor gene control loci, contributing to cancer cell proliferation and survival. For example, in AML, BRD4 chromatin occupancy is enriched at enhancer and promoter regions and highly correlated with the distribution of PU.1, FLI1, ERG, C/EBPα, C/EBPβ, and MYB (13) . BRD4 inhibition interferes with the functional output of these lineage-specific transcription factors, and thereby inhibits AML maintenance. In MM the survival of malignant plasma cells is dependent on MYC transcriptional activity. MYC deregulation in MM can occur through gene translocation, amplification and overexpression (14, 15) . In this setting BRD4 inhibition disrupts MYC activity and results in MM cell cycle arrest and senescence (16) . DLBCL is a biologically and clinically heterogeneous disease, which is similarly typified by the activation of lineage-specific and growth-associated transcription factors including NF-B, BCL6, p53, and MYC (17) (18) (19) (20) . BRD4 inhibition downregulates oncogenic MYC and E2F transcriptional pathways, resulting in antiproliferative effects across DLBCL subtypes (21) . Based on this and other work, several drug candidates targeting BRD4/BET have progressed into clinical trials to treat Nut Midline Carcinoma (NMC), AML, Myelodysplastic Syndromes (MDS), MM, DLBCL, Glioblastoma Multiforme, and other solid tumors.
We recently described the discovery of BET bromodomain inhibitors that are chemically distinct from the commonly described benzodiazepine-based scaffold and capable of a novel bivalent binding mode (22) . A dedicated medicinal chemistry campaign led to the discovery of a BET inhibitor clinical candidate AZD5153 (23) . In this study, we characterize the in cell bivalent binding mode of AZD5153 and demonstrate the cellular and pharmacological advantages achieved through the unique biophysical properties of AZD5153 using AML, MM, and DLBCL as model systems.
Materials and Methods

Cell lines and Reagents
Most of cell lines were purchased from ATCC or DSMZ and a few obtained from academic laboratories from 2006 to 2014, and cultured according to providers' instructions (detailed information in Supplementary Table 1) . Cell lines were authenticated using DNA fingerprinting short-tandem repeat (STR) assays and confirmed to be free of bacterial and viral contaminations by IDEXX (Westbrook, ME). All cell lines were used within15 passages, and less than 6 months. Antibodies used for western blot analysis were from Cell Signaling
(S235/236) (#4856), anti-S6 (#2217), anti-phospho-4EBP1 (S65) (#9451), and anti-4EBP1 (#9644).
Bioluminescence Resonance Energy Transfer (BRET) NanoBRET assay
The BRD4 NanoBRET assays have been previously described (24) . Briefly, the expression construct of Histone H3.3-Halotag (NM_002107), was co-transfected with either NanoLuc-BRD4 full-length (1-1362) (060885), NanoLuc-BRD4 full-length N433F mutant, or NanoLuc-N-terminal BRD4-BD1 (amino acids 44-168) expression vector into HCT116 cells. Cells were then seeded into 384-well plates and treated with various concentrations of compounds.
Plates were read after 18 hours of compound treatment.
Immuno-fluorescent assays for BRD4 chromatin displacement
The Immuno-fluorescent assays have been previously described (24) . Briefly, BRD4 foci were stained by using anti-BRD4 antibody (Sigma Aldrich, HPA015 HPA015055) and secondary anti-rabbit antibody labeled with Alexa Fluor 488. The specificity of BRD4 antibody was verified by siRNA BRD4 knockdown in U2OS cells (24) . Image acquisition was carried out by ImageXpress MicroXL High Content Screening System (Molecular Devices) and data analysis by MetaXpress (Molecular Devices). 
MYC Flow assay
Cell anti-proliferation and viability assays
Sixty-one cell lines were cultured in appropriate medium. Optimal 384-well seeding densities were pre-measured for linear growth over 72 hours. 30 µl cells/well were seeded in black, flat bottom 384-well plates and treated with compounds for 72 hours. The viable cells were measured using Alamar Blue reagents following manufacture's protocol (Invitrogen). The percent net growth is calculated by normalizing against the no-drug controls, and the GI50 value, the concentration that causes 50% net growth inhibition, was calculated using GraphPad Prism 6.
Viability assay was performed following the same protocol as the anti-proliferation assay but differed in data treatment. Absolute number of remaining viable cells, instead of percent net growth, was determined after 72 hours of compound treatment. Cell viability IC50 value was obtaining by fitting the raw data points with sigmoidal nonlinear regression and IC50 curves were plotted using GraphPad Prism6.
FACS apoptosis assay
Apoptosis was analyzed by flow cytometry using CellEvent Caspase 3/7 Green detection reagent (ThermoFisher, #C10423 version 3.12.0 was used to identify differentially expressed genes using trimmed mean of M values for normalization and the exactTest method for differential expression. All RNAseq data were deposited at GEO (GSE85840).
Gene Set Enrichment Analysis
Gene set enrichment analysis (GSEA) [16199517, 12808457] 
Reverse phase protein microarray (RPPA) for proteomic profiling
Proteomic profiling was carried out using high-density protein dot blot-based immunoassay system provided by Theranostics (Gaithersburg, MD). Cells were treated with 200 nM AZD5153 for 24 hour, protein lysates prepared following Theranotics' protocol, and samples shipped to Theranostics to perform the array study. A total of 182 endpoints were assessed by immunostaining with corresponding antibodies. Data acquisition, quality control, and normalization were performed by Theranostics. AZD5153-modulated protein targets were identified by performing a paired, two-sided Student's T-test between DMSO and AZD5153 treated samples
Quantitative PCR
Cell pellets containing ~1x10 6 cells or ~10 mg of tumor tissue were collected. RNA was extracted using an RNAeasy mini kit and manufacturer's protocol (Qiagen, cat# 74104). RNA was converted to cDNA with a High Capacity RT kit following manufacturer's protocol (Applied Biosystems, cat#4368814). PCR was performed using Taqman Gene Expression Master Mix (Applied Biosystems, cat#4369016) with 300 ng of cDNA and taqman probes (Applied Biosystems, # MYC-Hs00153408_m1, #HEXIM1-Hs00538918_s1, and #GAPDH control-4352934E) on ABI Prism 7900HT instrument.
Efficacy and PK/PD studies in vivo xenograft models
Female CB17 SCID and SCID beige mice were obtained from Charles River (Wilmington, MA) and NSG mice from Jackson Labs (Bar Harbor, ME). All animals were used in compliance with protocols approved by the Institutional Animal Care and Use Committees of AstraZeneca.
Between 5x10 
Immunohistochemical (IHC) analysis
Formalin fixed tumors were subjected to processing through graded ethanol, xylene and paraffin, embedded into paraffin blocks and 3 μm sections were cut for assays. IHC was run with an optimized protocol on the Ventana Discovery XT using anti-Myc primary rabbit polyclonal antibody (Millipore #06-340) at a 1:200 dilution, biotinylated anti-rabbit secondary antibody (Vector Labs #PK-6101) and the DABMap detection kit (Ventana Medical #760-124).
For cleaved caspase 3, IHC was run with an optimized protocol on the Ventana Discovery XT using anti Cleaved Caspase 3 primary rabbit polyclonal antibody (CST-9661) at a 1:5000 dilution, biotinylated anti-rabbit secondary antibody (Vector Labs #PK-6101) and the DABMap detection kit (Ventana Medical #760-124). Digital slide images were acquired for both antibodies with the Aperio Scanscope XT using a 20X objective. Viable tumor areas were manually selected in Aperio Imagescope (version 11), and percent positive nuclei were quantified using a modified Nuclear Algorithm (version 9).
Modulation of PD Biomarkers in human whole blood
Whole blood was collected from six healthy donors and incubated with DMSO or 100 nM AZD5153 for 2 hours at 37°C. The whole blood was transferred to PAXgene RNA tubes (BD Diagnostics), incubated for 2 hours at room temperature for RNA stabilization and stored at -20°C until RNA extraction. RNA extraction was performed using PAXgene Blood RNA kits (Qiagen) according to manufacturer's instructions. Total RNA was then quantified, reverse transcribed and used as template for quantitative PCR using primers (ABI) specific for MYC and HEXIM1. Data was normalized using GAPDH as the housekeeping gene and converted to relative signal (2 -ΔCt )*100 to calculate percent of control.
Results
AZD5153 is a potent BET bromodomain inhibitor possessing a bivalent binding mode
AZD5153, as shown in Figure 1A , is a potent and selective BET bromodomain inhibitor. Figure 1A) . In comparison, the monovalent inhibitor JQ1 showed a similar chromatin displacement dose-response between the mutant and wild-type protein (Supplemental Figure   1B ). Taken together, these data provide compelling evidence that the bivalent binding mode is the binding mechanism for AZD5153 in cells.
Avidity of bivalent binding leads to enhanced cellular potency with increased BRD4 displacement from chromatin and MYC modulation
We previously established a quantitative immuno-fluorescent assay to examine BRD4 chromatin displacement by measuring the disruption of BRD4 foci which are resulted from highly asymmetric binding of BRD4 to the enhancer regions (22) . In this assay, AZD5153
potently disrupted BRD4 foci in U2OS cells with an IC50 value of 1.7 nM ( Figure 1D -E). In contrast, the monovalent inhibitor I-BET762 had an IC50 of 36.0 nM in the same assay ( Figure   1E ). 
AZD5153 modulates E2F, MYC, and mTOR transcriptional programs
To gain further understanding of the underlying cellular mechanism of phenotypic response and to facilitate biomarker discovery, we performed RNA-sequencing on a panel of Table 1) . Consistent with previous studies of BET inhibition, differential expression of HEXIM1, MYC, BCL2, FOSL1, and E2F1 was observed in select or multiple cell line types (16, (25) (26) (27) . Gene Ontology (GO) analysis (28) was performed on the 109 uniformly down-regulated transcripts by AZD5153. Genes involved in G1/S transition and cell cycle progression were highly enriched, suggesting that the intersecting genes function in core cellular processes (Supplementary Figure 3) . We used Gene Set Enrichment Analysis (GSEA) (29, 30) to gain a more comprehensive understanding of AZD5153 inhibitory effects on biological hallmarks and transcription factors using all cell line and tumor-specific data ranked by differential expression. Significant gene sets identified in at least one comparison (FDR < 0.1) were ranked and represented by a heat map. Similar correlating hallmarks were noted across all tumor types and included transcriptional targets of MYC, E2F transcription factors, and mTOR signaling components ( Figures 3B -3E ).
Repression of mTOR signaling is an AZD5153 sensitivity correlate
In order to determine the consequences of BRD4 inhibition on protein levels, we used reversephase protein array (RPPA) technology to quantitatively examine the expression of 182 totaland phospho-proteins following 24 hours of AZD5153 treatment (200 nM) in K562, IM9, MOLP8, MV-4-11, and OCILY19 cell lines (Supplementary Table 2 ). To identify protein modulation that correlated with sensitivity to AZD5153, we segregated cell lines into resistant (K562, IM9) and sensitive (MOLP8, MV-4-11, OCILY19) groups based on a GI50 cutoff of 100 nM. Interestingly, RPPA revealed that cell lines sensitive to AZD5153 exhibited a marked decrease in the level of mTOR-pathway associated proteins following AZD5153 treatment ( Figure 4A ). Selective down-regulation of p-p70S6K, PRAS40, and p-4EBP1 in AZD5153-sensitive cell lines was confirmed by western blot with multiple doses of AZD5153 ( Figure 4B ).
In contrast, MYC modulation was observed in both sensitive and resistant cell lines ( Figure   4B ), suggesting that MYC downregulation was not sufficient to modulate cell survival. These data suggest that in hematologic malignancies, mTOR pathway downregulation may serve as an appropriate biomarker of sensitivity to BRD4 inhibitors such as AZD5153.
AZD5153 demonstrates potent anti-tumor activity in hematologic xenograft models
In order to assess the in vivo activity of AZD5153, we explored the effects of dosing AZD5153
in AML, MM, and DLBCL xenografts. MLL-fusion leukemia has previously been shown to be dependent on BRD4 (26, These data demonstrate AZD5153 is efficacious in a range of hematologic malignancies in vivo.
Duration of BRD4 inhibition is the driver for efficacy and sustained BRD4 inhibition led to near complete tumor regression
In an effort to understand if increased daily target coverage could drive greater efficacy, we evaluated QD, BID, and continuous dosing delivered via a subcutaneous mini-pump in MV-4- mg/kg/daily, equivalent to 35 mg/kg/week, is needed to achieve a comparable efficacy to the 6.4 mg/kg/week continuous dose ( Figure 5D ). The steady and prolonged BRD4 inhibition achieved with the mini-pump was associated with increased apoptosis in the tumors compared with daily oral dosing after 7 days of treatment ( Figure 5E-F) . However, 12.8 mg/kg/week minipump group, that was twice the efficacious dose of 6.4 mg/kg/week, was accompanied by significant body weight loss with an average weight loss of 10% observed. Taken together, these results support that the duration of BRD4 inhibition is the primary driver for in vivo efficacy, and additional dose/schedule investigation is needed to determine an appropriate balance of target coverage and tolerability to maximize the therapeutic benefit.
Pharmacodynamic evaluation in xenograft models and human whole blood supports MYC and HEXIM1 as biomarkers for AZD5153 inhibition
To understand the pharmacokinetic (PK)/PD relationship of AZD5153, MYC mRNA and protein levels were measured by quantitative PCR (qPCR) and western blot. The concentration of AZD5153 was also measured in the plasma of the corresponding mouse after a single oral dose of 2.5, 5, or 10 mg/kg in MV-4-11 xenografts. All three doses induced significant modulation of MYC mRNA and protein over the first 8 hours but largely recovered by 16 hours (Figures 6A and 6D ). There was an inverse correlation between AZD5153 concentration in plasma and MYC mRNA levels in tumors ( Figure 6A ). Significant inhibition of MYC mRNA was achieved with free plasma concentration as low as 0.1 µM of AZD5153 in mice with MV-4-11 tumors. The MYC mRNA levels returned to baseline as AZD5153 was cleared from the plasma. In contrast, HEXIM1 mRNA was up-regulated by AZD5153 treatment and had a similar but inverse PK/PD relationship (data not shown). An example of such a relationship is shown in Figure 6F , when mRNA levels of MYC and HEXIM1 were determined at 2 hours post the 5mg/kg dose, MYC mRNA was down-regulated by about 80% whereas HEXIM1 mRNA was up-regulated by 400% ( Figure 6F ).
To confirm MYC protein modulation by AZD5153 and understand the heterogeneity within the tumors, immunohistochemistry (IHC) was performed in MV-4-11 tumors after 20 mg/kg dosing. As shown in Figure 6B 
Discussion
Herein, we assessed the characteristics of AZD5153, a novel BET bromodomain inhibitor. The bivalent binding mode of AZD5153 sets it apart from previously described BET bromodomain inhibitors. Mechanistically, the simultaneous ligation of both BRD4 bromodomains by AZD5153 allows for efficient displacement of BRD4 from chromatin at lower drug concentrations. This unique biophysical property translates into enhanced in vitro and in vivo pharmacological activity.
In the hematologic tumor setting, our comparative efficacy studies with QD, BID and continuous dosing of AZD5153 have revealed that duration of target coverage is the primary driver for in vivo efficacy. Twice daily dosing with the split QD dose mitigated the issue of fast clearance of AZD5153 from the mouse system and provided longer duration of target inhibition translating into better efficacy. We enhanced these findings by employing mini-pump drug infusion, which eliminates PK fluctuations, and provides consistent target inhibition. Compared to daily oral dosing, less than one fifth of AZD5153 was needed per week via mini-pump to achieve comparable efficacy. Furthermore, our data indicate Cmax does not play a significant role in driving AZD5153 efficacy. Namely, there was a greater than 12 fold difference in Cmax between 5 mg/kg/daily oral and 6.4 mg/kg/week mini-pump infusion. Unfortunately, enhanced efficacy achieved through prolonged target inhibition was often accompanied by significant body weight loss, which we used as a surrogate for gastrointestinal toxicity for BET inhibitors in mice. However, there remains a therapeutic index at lower doses using continuous infusion or a daily oral schedule, thus allowing for anti-tumor activity without concomitant bodyweight loss. Sustained BRD4 inhibition for a period of 2-3 days could lead to in vitro cell death of MV-4-11 cancer cells via apoptosis, suggesting that an intermittent schedule is sufficient to deliver efficacy. Further investigation is needed to validate if such a schedule can sufficiently induce tumor cell death, while minimizing toxicity within normal tissues. Moreover, BET bromodomain inhibitors may have different scheduling requirements in solid tumor settings, owing to differences in tumor biology and microenvironment. A systematic investigation of both dose and schedule will be required to find the appropriate balance of drug exposure, efficacy, and tolerability for the myriad of disease subtypes for which BRD4 is being prosecuted as a cancer drug target. Ongoing clinical studies will no doubt be critical to define the optimal use of the BET bromodomain inhibitors.
Our gene expression analysis characterized the transcriptional response induced by AZD5153
in AML, MM, and DLBCL. Consistent with previously described studies examining BET bromodomain inhibitors, we observed significant modulation of MYC and E2F gene programs.
However, our study is the first, to our knowledge, to reveal a significant modulation of an mTOR gene signature in these tumor types. Furthermore, we demonstrated that modulation of the mTOR signaling correlates with sensitivity to AZD5153 in cell lines we studied whereas MYC levels do not. Our data suggest that modulation of the mTOR pathway, which is widely 
